Literature DB >> 16304219

Intensive care unit readmission after elective coronary artery bypass grafting.

Joseph Alex1, Rajesh Shah, Steven C Griffin, Alexander R J Cale, Michael E Cowen, Levent Guvendik.   

Abstract

Prospective data of 3,120 consecutive patients who had elective coronary artery bypass were analyzed to identify patient profile, cost, outcome and predictors of those readmitted to the intensive care unit. Group A (n=3,002) had a single intensive care unit admission and group B (n=118) were readmitted within 30 days after surgery. Parsonnet score, EuroSCORE, age, body mass index, chronic obstructive airway disease, peripheral vascular disease, renal dysfunction, unstable angina, congestive cardiac failure, and poor left ventricular function were higher in group B. Bypass and crossclamp times were longer, and the prevalence of inotropic and balloon pump support, arrhythmias, myocardial infarction, re-exploration, blood loss and transfusion, cerebrovascular accident, wound infection, sternal dehiscence, and multisystem failure were higher in group B. Despite a 4-fold increase in cost of care, the mortality rate (32.4%) of patients readmitted to intensive care was 23-times higher than routine patients (1.4%). Crossclamp time>80 min, Parsonnet score>10, EuroSCORE>9, sternal dehiscence, ventricular arrhythmias, and renal failure predicted readmission.

Entities:  

Mesh:

Year:  2005        PMID: 16304219     DOI: 10.1177/021849230501300407

Source DB:  PubMed          Journal:  Asian Cardiovasc Thorac Ann        ISSN: 0218-4923


  2 in total

1.  Readmission To Intensive Care Unit After Coronary Bypass Operations in the Short Term.

Authors:  Funda Gümüş; Adil Polat; Abdülkadir Yektaş; Vedat Erentuğ; Ayşin Alagöl
Journal:  Turk J Anaesthesiol Reanim       Date:  2014-05-29

2.  Renal effects of dexmedetomidine during coronary artery bypass surgery: a randomized placebo-controlled study.

Authors:  Kari Leino; Markku Hynynen; Jouko Jalonen; Markku Salmenperä; Harry Scheinin; Riku Aantaa
Journal:  BMC Anesthesiol       Date:  2011-05-23       Impact factor: 2.217

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.